Ryan Halsted
Stock Analyst at RBC Capital
(1.28)
# 3,546
Out of 4,457 analysts
73
Total ratings
57.8%
Success rate
-1.1%
Average return
Main Sectors:
Stocks Rated by Ryan Halsted
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ICLR ICON Public Limited Company | Upgraded: Buy | $126 → $185 | $172.99 | +6.94% | 3 | Jun 25, 2026 | |
| DOCS Doximity | Maintained: Buy | $28 | $20.59 | +35.99% | 8 | Jun 24, 2026 | |
| CRL Charles River Laboratories International | Reiterated: Buy | $215 | $225.57 | -4.69% | 3 | Jun 4, 2026 | |
| HQY HealthEquity | Reiterated: Buy | $108 | $87.81 | +22.99% | 2 | Jun 3, 2026 | |
| PHR Phreesia | Maintained: Buy | $19 | $10.29 | +84.65% | 5 | May 27, 2026 | |
| SHC Sotera Health Company | Reiterated: Buy | $24 | $17.52 | +36.99% | 8 | May 22, 2026 | |
| EVH Evolent Health | Reiterated: Hold | $3 | $5.77 | -48.01% | 4 | May 7, 2026 | |
| PRVA Privia Health Group | Reiterated: Buy | $31 | $25.55 | +21.33% | 6 | May 7, 2026 | |
| MDLN Medline | Reiterated: Buy | $53 | $39.61 | +33.80% | 5 | May 7, 2026 | |
| IQV IQVIA Holdings | Reiterated: Buy | $221 | $193.28 | +14.34% | 4 | May 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $44 | $19.98 | +120.22% | 6 | Apr 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $522 → $484 | $534.72 | -9.49% | 4 | Apr 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $22 → $24 | $24.50 | -2.04% | 3 | Apr 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $23 | $26.18 | -12.15% | 3 | Apr 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | n/a | $15.86 | n/a | 4 | Jan 12, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $39.67 | n/a | 1 | Oct 6, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $76.54 | n/a | 1 | Sep 9, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $22 | $158.19 | n/a | 3 | May 12, 2016 |
ICON Public Limited Company
Jun 25, 2026
Upgraded: Buy
Price Target: $126 → $185
Current: $172.99
Upside: +6.94%
Doximity
Jun 24, 2026
Maintained: Buy
Price Target: $28
Current: $20.59
Upside: +35.99%
Charles River Laboratories International
Jun 4, 2026
Reiterated: Buy
Price Target: $215
Current: $225.57
Upside: -4.69%
HealthEquity
Jun 3, 2026
Reiterated: Buy
Price Target: $108
Current: $87.81
Upside: +22.99%
Phreesia
May 27, 2026
Maintained: Buy
Price Target: $19
Current: $10.29
Upside: +84.65%
Sotera Health Company
May 22, 2026
Reiterated: Buy
Price Target: $24
Current: $17.52
Upside: +36.99%
Evolent Health
May 7, 2026
Reiterated: Hold
Price Target: $3
Current: $5.77
Upside: -48.01%
Privia Health Group
May 7, 2026
Reiterated: Buy
Price Target: $31
Current: $25.55
Upside: +21.33%
Medline
May 7, 2026
Reiterated: Buy
Price Target: $53
Current: $39.61
Upside: +33.80%
IQVIA Holdings
May 5, 2026
Reiterated: Buy
Price Target: $221
Current: $193.28
Upside: +14.34%
Apr 29, 2026
Reiterated: Buy
Price Target: $44
Current: $19.98
Upside: +120.22%
Apr 23, 2026
Reiterated: Buy
Price Target: $522 → $484
Current: $534.72
Upside: -9.49%
Apr 22, 2026
Reiterated: Hold
Price Target: $22 → $24
Current: $24.50
Upside: -2.04%
Apr 13, 2026
Maintained: Hold
Price Target: $23
Current: $26.18
Upside: -12.15%
Jan 12, 2017
Upgraded: Buy
Price Target: n/a
Current: $15.86
Upside: n/a
Oct 6, 2016
Reiterated: Hold
Price Target: n/a
Current: $39.67
Upside: n/a
Sep 9, 2016
Reiterated: Hold
Price Target: n/a
Current: $76.54
Upside: n/a
May 12, 2016
Reiterated: Hold
Price Target: $22
Current: $158.19
Upside: n/a